NCT07340619: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
- State
- Not started
- Phase
- Phase 2
- People
- 51 planned
- Started
- 18 Sep 2026
- Primary completion
- 18 Nov 2028
- Arms
- Cohort 2 : prifetrastat incombination with fulvestrant
- Results
- None posted
- 14 Jan 2026: Trial registered